Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT

Pulmonary Hypertension Clinical Trial

Official title:

A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02036970
• Other study ID #: RTA 402-C-1302
• Status: Completed
• Phase: Phase 2
• Start date: May 31, 2014
• Est. completion date: May 16, 2018

Study information

• Verified date: February 2024
• Source: Biogen
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance (6MWD) and determine the effect of Bardoxolone methyl in pulmonary hypertension associated with connective tissue disease, interstitial lung disease, and idiopathic etiologies, including subsets of patients with WHO Group III or WHO Group V PH following 16 weeks of study participation.

Description:

The molecular and pharmacological effects of bardoxolone methyl are broad through its induction of Nrf2 and suppression of NF-κB. Bardoxolone methyl may therefore address multiple facets of the pathophysiology of PH because it suppresses activation of proinflammatory mediators, enhances endothelial NO bioavailability, improves metabolic dysfunction, suppresses vascular proliferation, and prevents maladaptive remodeling. Furthermore, while existing therapies primarily target only smooth muscle cells, bardoxolone methyl targets multiple cell types relevant to PH, including endothelial cells, smooth muscle cells, and macrophages. This is a two-part study. Part 1: Part 1 of the study will include a dose-ranging phase and a dose-titration phase. Part 2 (extension period): All patients from Part 1 who complete the 16-week treatment period as planned will be eligible to continue directly into the extension period to evaluate the intermediate and long-term safety and efficacy of bardoxolone methyl. Study Sponsor, originally Reata Pharmaceuticals, Inc., is now Reata Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 166
• Est. completion date: May 16, 2018
• Est. primary completion date: January 19, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Adult male and female patients = 18 to = 75 years of age upon study consent;

2. BMI > 18.5 kg/m²

3. Symptomatic pulmonary hypertension WHO class II and III;

4. WHO Group I, III, or V PH according to the following criteria:

1. If diagnosed with WHO Group I PAH, then on of the following subtypes:

• Idiopathic or heritable PAH;
• PAH associated with connective tissue disease;
• PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1 year following shunt repair;
• PAH associated with anorexigen or drug-induced toxicity;
• PAH associated with human immunodeficiency virus (HIV); or

2. If WHO Group III PH then primary diagnosis must be one of the following subtypes:

• Connective tissue disease associated ILD (CTD-ILD);
• Idiopathic pulmonary fibrosis (IPF);
• Nonspecific interstitial pneumonia (NSIP); or

3. If WHO Group V PH then patient must be diagnosed with sarcoidosis;

5. Had a diagnostic right heart catheterization performed and documented within 36 months prior to Day 1 that confirmed a diagnosis of PH

6. If WHO Group I, has been receiving no more than three (3) FDA-approved disease-specific PAH therapies except for intravenous (iv) prostacyclin/prostacyclin analogues. PAH therapy must be at a stable dose for at least 90 days prior to Day 1;

7. Has adequate kidney function defined as an estimated glomerular filtration rate (eGFR) = 45 mL/min/1.73 m2 using the Modification of Diet in Renal Disease (MDRD) 4-variable formula;

Exclusion Criteria:

1. Participation in other interventional clinical studies involving pharmaceutical products being tested or used in a way different from the approved form or when used for an unapproved indication within 30 days prior to Day 1;

2. Initiation of an exercise program for cardio-pulmonary rehabilitation within 3 months (90 days) prior to Day 1 or planned initiation during Part 1 of the study;

3. Stopped receiving any PH chronic therapy within 60 days prior to Day 1;

4. Requirement for receipt of intravenous inotropes within 30 days prior to Day 1;

5. Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure (BP) > 160 mm Hg or sitting diastolic blood pressure > 100 mm Hg during Screening after a period of rest;

6. Has systolic BP < 90 mm Hg during Screening after a period of rest;

7. WHO Group III or V patients who at rest require supplemental oxygen at a rate of >4 L/min and have peripheral capillary oxygen saturation levels <92%;

8. Has a history of clinically significant left-sided heart disease and/or clinically

significant cardiac disease,including but not limited to any of the following:

1. Congenital or acquired valvular disease if clinically significant apart from tricuspid valvular insufficiency due to pulmonary hypertension;

2. Pericardial constriction;

3. Restrictive or congestive cardiomyopathy;

4. Left ventricular ejection fraction < 40% per echocardiogram (ECHO) within 60 days of Day 1;

5. Any current or prior history of symptomatic coronary disease (prior myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or anginal chest pain);

9. Acutely decompensated heart failure within 30 days prior to Day 1, as per Investigator assessment;

10. History of atrial septostomy within 180 days prior to Day 1;

11. History of obstructive sleep apnea that is untreated;

12. Has a history of portal hypertension or chronic liver disease, including hepatitis B and/or hepatitis C (with evidence of recent infection and/or active virus replication) defined as mild to severe hepatic impairment (Child-Pugh Class A-C);

13. Serum aminotransferase (ALT or AST) levels > the upper limit of normal (ULN) at Screening;

14. For patients with HIV-associated PAH, any of the following:

1. Concomitant active opportunistic infections within 180 days prior to Screening;

2. Detectable viral load within 90 days prior to Screening;

3. Cluster designation (CD+) T-cell count < 200 mm3 within 90 days prior to Screening;

4. Changes in antiretroviral regimen within 90 days prior to Screening;

5. Using inhaled pentamidine

Related Conditions & MeSH terms

• Acute Interstitial Pneumonitis
• Bronchiolitis
• Cryptogenic Organizing Pneumonia
• Desquamative Interstitial Pneumonia
• Fibrosis
• Hypertension
• Hypertension, Pulmonary
• Idiopathic Interstitial Pneumonia
• Idiopathic Interstitial Pneumonias
• Idiopathic Lymphoid Interstitial Pneumonia
• Idiopathic Pleuroparenchymal Fibroelastosis
• Idiopathic Pulmonary Fibrosis
• Interstitial Lung Disease
• Lung Diseases
• Lung Diseases, Interstitial
• Organizing Pneumonia
• Pneumonia
• Pulmonary Arterial Hypertension
• Pulmonary Fibrosis
• Pulmonary Hypertension
• Respiratory Bronchiolitis Associated Interstitial Lung Disease
• Sarcoidosis

Intervention

Drug:
• Bardoxolone methyl

• Placebo

Locations

Country	Name	City	State
Germany	University Clinic Carl Gustav Carus	Dresden
Germany	Universitaetsklinikum Hamburg-Eppendorf	Hamburg
United States	University of Colorado Denver - Division of Pulmonary Sciences	Aurora	Colorado
United States	Cedars Sinai Medical Center	Beverly Hills	California
United States	Boston University School of Medicine	Boston	Massachusetts
United States	Brigham and Women's Hospital	Boston	Massachusetts
United States	Tufts Medical Center	Boston	Massachusetts
United States	University of Chicago	Chicago	Illinois
United States	The Lindner Clinical Trial Center	Cincinnati	Ohio
United States	University of Cincinnati - Department of Internal Medicine Pulmonary, Critical Care & Sleep Medicine	Cincinnati	Ohio
United States	The Ohio State University Wexner Medical Center	Columbus	Ohio
United States	University of Texas Southwestern Medical Center	Dallas	Texas
United States	BreatheAmerica El Paso, Inc.	El Paso	Texas
United States	Houston Methodist Research Institute	Houston	Texas
United States	The University of Texas - Health Science Center & Medical School at Houston	Houston	Texas
United States	University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics	Houston	Texas
United States	South Denver Cardiology Associates, P.C	Littleton	Colorado
United States	VA Healthcare System of Greater Los Angeles	Los Angeles	California
United States	Winthrop University Hospital	Mineola	New York
United States	Mount Sinai, Beth Israel Medical Center	New York	New York
United States	Weill Cornell Medical Center	New York	New York
United States	Oklahoma Heart Hospital	Oklahoma City	Oklahoma
United States	Arizona Pulmonary Specialists	Phoenix	Arizona
United States	Banner University Medical Center, Phoenix Advanced Lung Disease Institute	Phoenix	Arizona
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania
United States	Maine Medical Center - Division of Pulmonary and Critical Care Medicine	Portland	Maine
United States	University of Rochester - University of Rochester Medical Center	Rochester	New York
United States	University of California Davis Medical Center - Division of Pulmonary and Critical Care	Sacramento	California
United States	University of Utah	Salt Lake City	Utah
United States	Harbor - UCLA Medical Center	Torrance	California
United States	Georgetown University Medical Center - Department of Rheumatology	Washington	District of Columbia
United States	Cleveland Clinic of Florida	Weston	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Reata, a wholly owned subsidiary of Biogen

Countries where clinical trial is conducted

United States,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change From Baseline Though Week 16 in 6-Minute Walk Distance (6MWD) for Bardoxolone Methyl Compared to Placebo	Overall treatment effect in exercise capacity, as measured by the total distance walked in 6 minutes (6MWD) mean change from baseline though Week 16. A lower 6MWD reflects greater severity thus, a positive change from baseline suggests an improvement.	Baseline through Week 16